Psoralen (Synonyms:补骨脂素; Ficusin)
目录号 : KM13057 CAS No. : 66-97-7 纯度 : 98%

Psoralen (Ficusin) 是从补骨脂种子中提取的一种香豆素。Psoralen 具有多种生物学特性,包括抗癌、抗氧化、抗抑郁、抗癌、抗菌、抗病毒等。

规格 价格 是否有货 数量
10mg
In-stock
50mg
In-stock
100mg
In-stock
200mg 询价 In-stock
500mg 询价 In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

Psoralen (Ficusin) is a coumarin isolated from the seeds of Fructus Psoraleae. Psoralen exhibits a wide range of biological properties, including anti-cancer, antioxidant, antidepressant, anticancer, antibacterial, and antiviral, et al.

体外研究

Psoralen (10-500 μM; 24-48 hours) inhibits cell viability in a concentration- and time-dependent manner in L02 and HepG2 cells. In L02 cells, Psoralen at 400 μM does not significantly change extracellular LDH levels, and 400 μM or 450 μM psoralen inhibits 50–60% of cell viability.
Psoralen (150-450 μM; 24 hours) induces significant S-phase arrest in L02 cells in time- and dose-dependent manners, but it does not exhibits significant change in the cycle distribution of HepG2 cells.

Cell Proliferation Assay

Cell Line: L02 and HepG2 cells
Concentration: 10 μM, 50 μM,100 μM, 200 μM, 300 μM,400 μM,450 μM,500 μM
Incubation Time: 24 or 48 hours
Result: Inhibited the viability of L02 and HepG2 cells mainly by suppressing cell proliferation rather than causing cell death.

Cell Cycle Analysis

Cell Line: L02 and HepG2 cells
Concentration: 150 μM; 300 μM; 450 μM
Incubation Time: 24 or 48 hours
Result: Induced cell S-phase arrest instead of causing cell apoptosis or death.
体内研究

Psoralen (oral gavage; 17.5 mg/kg; 6 weeks) reduces the number of metastatic lesions and the rate of bone metastasis by 20% compared to vehicle-treated mice. It also reduces tumor infiltration and decreases the percentage of tumor cells in metastatic lesions by ~40% compared to vehicle in mice.

Animal Model: Female nude (BALB/c nu/nu) mice
Dosage: 17.5 mg/kg
Administration: Oral gavage; 17.5 mg/kg; 6 weeks
Result: Inhibited metastasis of breast cancer to bone in vivo.
分子式
C11H6O3
分子量
186.16
CAS号
66-97-7
中文名称
补骨脂素;补骨脂内酯;补骨酯素
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (537.17 mM; Need ultrasonic)

H2O : 1 mg/mL (5.37 mM; ultrasonic and warming and heat to 80°C)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 5.3717 mL 26.8586 mL 53.7172 mL
5 mM 1.0743 mL 5.3717 mL 10.7434 mL
10 mM 0.5372 mL 2.6859 mL 5.3717 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (13.43 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (13.43 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (13.43 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (13.43 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (13.43 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (13.43 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

临床试验
暂无相关参考文献
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2